StockData
First Tracks Biotherapeutics, Inc. logo

First Tracks Biotherapeutics, Inc. (TRAX) income statement

TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$44.50+0.93 (+2.13%)

Close on Nov 18, 2026Market cap $1.59BP/E –Yield –

First Tracks Biotherapeutics, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
9.16
Debt to equity
–
Debt to assets
–
Cash to current liabilities
860.3%

Valuation

P/E ratio
–
Price to sales
–
Price to book
10.53
Dividend yield
–

See a number that looks wrong?